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Conclusions: Patients with BM-UDP demonstrated comparable survival 
to those with BM-DP. The only prognosticator in our study for BM-UDP 
patients was KPS. Tailored therapeutic strategy with long-term 
palliative intent including WBRT and systemic therapies is reasonable 
for all BM-UDP patients with good performance status.  
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Purpose/Objective: Meningiomas account approximately for 15-20% of 
all primary brain tumours in adults. Neurosurgical resection has been 
considered the first treatment of choice but definitive radiotherapy 
(RT) or postoperative RT for sub-totally resected tumours is an 
integral modality in the treatment of meningiomas. Although short 
term toxicity from RT is uncommon, the potential late RT effects can 
be severe. Radiation treatment planning for Meningiomas can be 
challenging. The ultimate goal is to spare the critical structures while 
delivering the prescribed treatment dose to the target volume. A 
planning comparison was undertaken of both planning techniques to 
establish if there was a dosimetric advantage of VMAT compared with 
3D-CRT with particular reference to dose to PTV coverage and dose to 
normal brain. 
Materials and Methods: 12 patients (8 females, 4 males) with 
Meningioma have been treated over the past 18 months. 60% of 
patients received RT following surgical resection. All patients were 
planned with 3D-CRT and VMAT, optimising dose to tumour. Total dose 
was 50.4Gy in 28 fractions. The GTV was delineated on CT/MRI co-
registered images. A CTV-PTV margin of 0.7cm was added. The 
median treatment volume was 111cc (56-190). Analytical Anisotropic 
Algorithm (AAA) was used to calculate the plans. 
Results: For the PTV, the comparison parameters include mean dose 
and conformation number. Calculation of the conformation number 
(CN) took into account the coverage of the PTV and volume of healthy 
tissue receiving dose above the prescribed dose. 1 is the ideal value. 
Mean PTV dose: 3D-CRT 50.7Gy (range 41.3Gy-54.7Gy) ±4.2 (SD),  
VMAT 50.6Gy (range 50.3Gy-53.9Gy) ±1.3 (SD). 
CN for 3DCRT = 0.446 (range 0.32-0.550) 
VMAT = 0.823 (range 0.70-0.90).  
Absolute improvement in CN in VMAT plans over 3D-CRT was 0.352 
(range 0.206-0.508). 
Normal brain doses :V45 3D-CRT 5.93% (range 3.3%-14.3%), VMAT 
1.41% (range 0.8%-3.8%).  
V10 3D-CRT 38.5% ( range 24.2%-46.9%), VMAT 33.7% (range 24.7%-
55.9%) 
Conclusions: 3D-CRT and VMAT plans achieved equivalent PTV 
coverage. However, VMAT plans achieved superior homogeneity. The 
CN varies considerably leading us to conclude that the PTV coverage 
in the 3D-CRT plans is sub optimal. Although the CN for the VMAT is 
not ideal, it is substantially better. V 45Gy is better in the VMAT plans 
however, V10 is comparable.  
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Purpose/Objective: The aim of the work was to evaluate changes in 
NAA,Cho, lactate and lipid peaks after radiotherapy of partially 
operated gliomas as compared with 1H-MRS data gained before 
radiotherapy. Proton magnetic resonance spectroscopy gives 
information related to cell membrane proliferation, neuronal function 
metabolism and necrotic transformation of brain or tumor tissues. 
Spectroscopy added to MRI helps in tissue characterization of 
intracranial lesions, which could be of help in diagnostic of local brain 
disease. MRS could be helpful in the differentiation of high grade from 
low grade brain tumors, and perhaps in separating recurrence from 
radiation injury. Reduction in the resonance intensity of NAA (N-
acetylaspartate) in the white matter of the brain in MR spectroscopy 
investigations reflects changes in metabolism or axonal density. Active 
demyelization produces changes in the resonance from choline. 
Lactate increases with inflammation due to anaerobic metabolism of 
inflammatory cells,associated mitochondrial dysfunction or occlusion 
of micro vessels. In normal brain NAA produces the highest peak in 
MRS examination. Gliomas malignancy tends to increase with decrease 
in NAA levels. Cho increases at a higher rate with more rapid 
development of neoplasm. Cho is one of the components of membrane 
metabolites and reflects membrane turnover. The presence or 
elevation of lactate and lipid has been attributed to rapid tumor 
growth and necrosis and indicates high tumor grade. Cho peak is 
identified as a marker of tumor cell proliferation. 
Materials and Methods: 52 patients with gliomas with partial 
resection of tumors were subjected to MRI with 1H-MRS examination 
before and after radiotherapy (60 Gy, 2 Gy/day). NAA, Cho, lactate 
and lipid peaks before irradiations were chosen as basic values. 
Results: Changes in peak intensity after radiotherapy depend on the 
malignancy grade of the tumor. Lactate and lipid levels were reduced 
after radiotherapy. NAA level increased. Cho changes were 
unpredictable especially for tumors with high grade of malignancy. 
Changes in NAA, Cho, lipid and lactate peaks could help in evaluation 
of radiotherapy effectiveness and in detection of early recurrence in 
gliomas. 
Conclusions: Changes in peaks intensity after irradiation could be of 
prognostic values. 
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Purpose/Objective: To determine role of irradiation in the treatment 
of patients with advanced Hodgkin’s disease (HD) and bone marrow 
(BM) involvement.  
Materials and Methods: 632 patients (pts) with advanced HD were 
included in this retrospective analysis. In all cases diagnosis of HD 
were confirmed by histology. Extranodal lesions diagnosed in 206 of 
632 pts. Since 1992 whole body BM scintigraphy with 99m??-
nanocolloids visualization is a part of routine staging. All cases of BM 
lesions revealed by scintigraphy were verified by biopsy, additional 
instrumental survey and by follow-up. All pts receive 4-8 cycles of 
chemotherapy with MOPP-ABVor ABVD or BEACOPP. In 45 pts 
visualized BM lesions were irradiated within 20Gy-50Gy (average dose 
38.1Gy). BM lesions were outside radiation fields in another 30 cases. 
Results: In 206 pts with extranodal disease BM invasion revealed in 75 
(36%) cases: 51 pts had one-two BM lesions and another 21 – multifocal 
BM involvement. Overall (OS) and disease free (DFS) 10 year survival 
in pts with BM invasion (49% and 45%) were significantly (p=0,026) 
lower than in other pts with extranodal HD (62% and 65%). In pts with 
only BM involvement and those with BM and other extranodal invasion 
OS and DFS were comparable: 50% versus 47.5% and 48.5 versus 41%. 
On the contrary, OS was significantly different (p=0.014) in pts with 1-
2 BM lesions (57%) and multifocal BM disease (26.5%). Irradiation of BM 
lesions significantly improve 10 year OS (p=0.00005) and DFS (p=0.006) 
in pts with HD: from 16% to 68% and from 23% to 58.5% 
correspondingly. It is especially important that this differences is 
preserved for pts with 1-2 BM foci: 10 year OS and DFS in cases of 
irradiated BM lesions are 72.7% and 57.5% versus 13.5% and 25% - in 
non irradiated BM lesions (p=0.0006 and p=0.054).  
Conclusions:  
1. In pts with advanced HD and BM involvement irradiation of 
visualized BM lesions significantly improve 10 year OS and DFS. 
2. Visualization of BM lesions is of crucial importance for radiotherapy 
planning.  
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Purpose/Objective: MRIs provide us sufficient information regarding 
the tumor bulk, but a little for the infiltrating tumor cells. For the 
precise planning of the irradiation for infiltrating tumors such as 
gliomas, more biological imagings were required to delineate the 
target, and Methinoine(Met)-PET may be one of the candidates. In this 
study, we evaluated the correlations between Met-uptake before 
irradiation, delivered dose and control of the lesions to elucidate the 
optimal dose to control lesions owing to the Met-uptakes. 
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Materials and Methods: 30 lesions from 23 malignant astrocytomas (2 
AAs and 21 GBMs) were enrolled. Before irradiation, Met-PET was 
performed in all cases. In each ROI, maximum uptake of Met was 
determined relative to a corresponding contralateral region 
(Tmax/Nave). Among the 23 patients, 10 were treated by 3D-CRT with 
conventional fractionation (40Gy/20Fxs for FLAIR-high area with boost 
of 20Gy/10Fxs for enhanced lesion), while the remaining 13 were 
treated by hypofractionated high-dose IMRT. In the IMRT, 3-layered 
PTVs were contoured (PTV-1: enhanced lesion with 5mm margin, PTV-
2: 15mm surrounding the PTV-1,PTV-3: FLAIR-high area) and different 
doses (68Gy for PTV-1, 40Gy for PTV-2 and 32Gy for PTV-3) were 
delivered by 8 fractions. Concurrent and adjuvant temozolomide was 
administrated in all cases. After treatment, MRI was performed with 
an interval of 1 or 2 months. If the recurrent tumor was observed, 
Met-uptake at the recurrent point and delivered dose at the same 
point in the treatment plan of irradiation were retrospectively 
calculated. The delivered dose was standardized using biologically 
effective dose (BED, alpha/beta=10). The ratio of Met-uptake/BED 
was compared with tumor control using logistic regression analysis, 
and optimal threshold was calculated from ROC curves. The patients 
were divided into two groups using this threshold and progression-free 
survival was compared. 
Results: Among the 30 lesions, 16 recurrences were observed within 
one year after irradiation, while 9 lesions were well controlled for 
more than one year. Five lesions without recurrence were excluded 
because the follow-up period not reached one year. Met-uptake/BED 
was significantly correlated with the control of the lesion (p=0.020). 
The optimal threshold of Met-uptake/BED was calculated as 0.029. 
The progression-free survival time with low Met-uptake/BED (20.2m) 
was significantly longer than the others (4.4m, p=0.004). MGMT-
methylation status also showed borderline significance, but the 
independent significance of Met-uptake/BED was ascertained with 
multivariate analysis (p=0.007). Required dose to control lesions could 
be decided upon the Met-PET using the following formula: BED= Met-
uptake/0.029. 
Conclusions: Required BED to control tumor was significantly 
correlated with the Met-uptake, and new treatment plan based upon 
Met-uptake was proposed. 
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Purpose/Objective: To improve results of treatment of ependymomas 
of the brain in children. 
Materials and Methods: In 1999 - 2011the children's department 
treated 129 children with ependymoma of the brain. All patients 
received after subtotal or partial removal of the tumor. 13% of 
patients on admission revealed metastases in the spinal cord. All 
patients received local or craniospinal radiotherapy with 
chemotherapy by vincristine. 84 (65%) children of radiation therapy 
was initiated within 4 to 7 weeks after surgical resection, and 45 (35%) 
- by 7 weeks after surgery. Daily single dose of 1.8-2Gr/d, total focal 
dose tothe primary tumor area is 55Gr, with craniospinal irradiation 
35Gr the entire volume of CSR. 
Results: At follow-up in 53% of patients had local recurrence and 11% 
had metastases in the brain and spinal cord. There were significant 
differences in overall survival in patients who received radiation 
therapy in terms of 4 to7 weeks and 7 weeks later after surgery. The 
probability of death was in the 1.721 (HR) times lower than in group 1 
(P = 0.028, 95% Cl: 1.061-2.792), than in the second. Analysis of cases 
of recurrence showed that the main risk factor for recurrence was the 
volume of a surgical intervention: in the absence of post-operative 
MRI residual tumor recurrence rate was 17% and 83% of its stock. 
Conclusions: Patients appropriate radiation therapy no later than 4-7 
weeks after surgery. Accumulation of contrast material in the area of 
operation is undoubtedly a poor prognostic factor. The high frequency 
of local recurrence of the tumor demonstrates the need for 
modification techniques local irradiation in the presence of 
radiographic evidence of residual tumor. 
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Purpose/Objective: Whole brain radiotherapy (WBRT) is frequently 
employed in the palliation of brain metastases. Despite the 
introduction of CT-based simulation WBRT planning remains subject to 
both intra- and inter-observer variability. There is increasing 
recognition of the parotid glands as non-target organs-at-risk (OARs) in 
delivering WBRT. Quality of life is of prime importance in the 
palliative setting. Salivary gland dysfunction has the potential to 
adversely impact on quality of life. The purpose of this planning study 
was to develop a time efficient,user-friendly technique to minimise 
parotid dose without compromising target volume coverage in WBRT. 
Materials and Methods: Thirteen patients underwent CT-based 
simulation with orfit immobilization. Using the Varian Eclipse (v8.0) 
TPS, the clinical target volume (CTV) was delineated by auto-
segmentation of the brain. The planning target volume (PTV) was 
defined by adding a 5mm margin. Both parotid glands were contoured 
as OARs. Opposed lateral 6MV beams without collimator rotation were 
used and MLCs were automatically conformed to the PTV with an 
empiric 8mm margin. Dose calculation was performed for each patient 
using this virtual technique and also using a conventional simulation 
technique with collimator rotation. In this way each patient acted as 
his/her own control. We then compared parotid dose-volume 
statistics, target coverage and homogeneity. 
Results: Using the virtual simulation technique, the mean dose for the 
combined parotid glands was reduced to 6.4Gy, compared with 10.9Gy 
using the conventional technique (p=0.026). The combined parotid 
V10, V25 and V30 were significantly reduced using the virtual 
simulation technique. 
Virtual Simulation 
N=13 
Conventional 
Simulation N=13 P Value 
Parotid Dose-Volume Statistics 
V 10 (%) 23.1 40.9 p=0.019
V 25 (%) 5.7 16.1 p=0.03 
V 30 (%) 0.6 5.5 p=0.002
D Min (Gy) 0.7 1 p=0.006
D Max (Gy) 30.8 31.4 p=0.016
Mean Parotid
Doses 
Right (Gy) [IQR] 7.3 [5.3-10.2] 11.2 [8.7-15.2] p=0.022
Left (Gy) [IQR] 6.2 [4.3-10.8] 10.6 [9.2-13.2] p=0.042
Combined 
(Gy)[IQR] 6.4 [4.9-11] 10.9 [9.5-14.5] p=0.026
PTV Coverage 
VPTV 95 (%) 99.6 99.9 p=0.02 
VPTV 107 (%) 5.3 7.7 p=0.058
V 107 (cc) 97.1 141.1 p=0.09 
 
There was no compromise in PTV coverage with the V95 over 99% 
using both techniques. Notably the virtual simulation technique also 
improved homogeneity as the VPTV107% was reduced (5.3% vs. 7.7%, 
p=0.058), although this finding was of borderline significance. 
Conclusions: This study suggests that significant reductions in 
radiation dose to the parotids and improved PTV homogeneity can be 
achieved with this virtual simulation technique. This technique is 
time-efficient, eliminates inter-observer variability and may reduce 
the risk of salivary gland dysfunction in palliative patients. 
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Purpose/Objective: To clarify the clinical significance of conventional 
and stereotactic radiotherapy for WHO grade II-III meningiomas. 
Materials and Methods: Clinical results of conventional and 
stereotactic radiotherapy for WHO grade II/III meningiomas treated 
between 1999 and 2011 were retrospectively reviewed. The patients' 
group included 28 patients with 37 treatment sessions (3 sessions for 2 
patients, 2 sessions for 5 patients, and other 21 patients were treated 
once). The median age of the patients at treatment were 70 years 
(range: 13-83 years). The patients experienced a median of 2 times 
(range: 1-5 times) of surgeries before radiotherapy. Pathological 
diagnoses at the most recent surgery were atypical meningiomas 
(WHO grade II)in 30 treatment sessions and anaplastic meningiomas 
(WHO grade III) in 7 sessions. Other subtypes of WHO grade II-III 
meningiomas were not treated in our institution within the period. 
Treatment sessions included 27 stereotactic radiosurgeries (SRSs) by 
